Clinical trialUNITERAREMay 5
New Recruiting Trial: Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis is testing a drug called asciminib in children who have a type of blood cancer called chronic myeloid leukemia (CML) that has a specific genetic change called the Philadelphia chromosome. This is a Phase 2 trial, which means researchers are checking if the drug works well and is safe in this younger age group. The study is now accepting patients and is expected to start in May 2026.
WHY IT MATTERSThis trial is the first to test asciminib specifically in pediatric patients with Ph+ CML-CP, potentially offering a new treatment option for children who may have limited alternatives or resistance to current therapies.